Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...

IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its ...

Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer. The “stage” (spread) ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

D. Boral Capital reiterated a ‘Buy’ rating and a $24 price target, implying nearly 300% upside from the stock's last close. ・Saudi regulators encouraged a filing for a bladder cancer therapy and ...

ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer. The stock climbed 32% to $7.94 on Wednesday.